COSIMO – patients with active cancer changing to rivaroxaban for the treatment and prevention of recurrent venous thromboembolism: a non-interventional study

BACKGROUND: Around 20% of venous thromboembolism (VTE) cases occur in patients with cancer. Current guidelines recommend low molecular weight heparin (LMWH) as the preferred anticoagulant for VTE treatment. However, some guidelines state that vitamin K antagonists (VKAs) and direct oral anticoagulan...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Alexander T., Maraveyas, Anthony, Beyer-Westendorf, Jan, Lee, Agnes Y. Y., Mantovani, Lorenzo G., Bach, Miriam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122180/
https://www.ncbi.nlm.nih.gov/pubmed/30186045
http://dx.doi.org/10.1186/s12959-018-0176-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122180/
https://www.ncbi.nlm.nih.gov/pubmed/30186045
http://dx.doi.org/10.1186/s12959-018-0176-2

Ejemplares similares